These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 7687521

  • 1. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.
    Rowland AJ, Pietersz GA, McKenzie IF.
    Cancer Immunol Immunother; 1993 Aug; 37(3):195-202. PubMed ID: 7687521
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
    Pietersz GA, Wenjun L, Sutton VR, Burgess J, McKenzie IF, Zola H, Trapani JA.
    Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
    [Abstract] [Full Text] [Related]

  • 3. Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin-monoclonal antibody conjugates.
    Smyth MJ, Foster HM, Andrew SM, Teh JG, Krauer K, McKenzie IF, Pietersz GA.
    Immunol Cell Biol; 1993 Jun; 71 ( Pt 3)():167-79. PubMed ID: 8349300
    [Abstract] [Full Text] [Related]

  • 4. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs.
    Rowland AJ, McKenzie IF, Pietersz GA.
    J Drug Target; 1994 Jun; 2(2):113-21. PubMed ID: 8069589
    [Abstract] [Full Text] [Related]

  • 5. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 6. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU.
    Int J Cancer; 1995 Jul 28; 62(3):337-44. PubMed ID: 7543082
    [Abstract] [Full Text] [Related]

  • 7. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 8. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM.
    Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120
    [Abstract] [Full Text] [Related]

  • 9. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling NR, Richardson PR, Hardie D, Wright DH.
    Br J Cancer; 1995 Dec 01; 72(6):1373-9. PubMed ID: 8519647
    [Abstract] [Full Text] [Related]

  • 10. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.
    Cancer Res; 1995 Feb 15; 55(4):840-6. PubMed ID: 7531616
    [Abstract] [Full Text] [Related]

  • 11. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES.
    Leukemia; 2003 Feb 15; 17(2):334-8. PubMed ID: 12592332
    [Abstract] [Full Text] [Related]

  • 12. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES.
    Blood; 1992 Nov 01; 80(9):2315-20. PubMed ID: 1384801
    [Abstract] [Full Text] [Related]

  • 13. Tumour eradication with high-dose idarubicin-anti-Ly-2.1 with murine tumour necrosis factor-alpha in mice.
    Pietersz GA, Bogdanovski M, Li W.
    Immunol Cell Biol; 1997 Jun 01; 75(3):253-8. PubMed ID: 9243290
    [Abstract] [Full Text] [Related]

  • 14. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
    Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM.
    Cancer Immunol Immunother; 1995 Jan 01; 40(1):37-47. PubMed ID: 7530170
    [Abstract] [Full Text] [Related]

  • 15. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
    Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA.
    Blood; 1992 Feb 01; 79(3):576-85. PubMed ID: 1370636
    [Abstract] [Full Text] [Related]

  • 16. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 Jun 15; 79(12):3116-29. PubMed ID: 1375841
    [Abstract] [Full Text] [Related]

  • 17. Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
    Van Horssen PJ, Preijers FW, Van Oosterhout YV, Eling WM, De Witte T.
    Leuk Lymphoma; 2000 Nov 15; 39(5-6):591-9. PubMed ID: 11342342
    [Abstract] [Full Text] [Related]

  • 18. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR, Vitetta ES.
    Leukemia; 2000 May 15; 14(5):853-8. PubMed ID: 10803517
    [Abstract] [Full Text] [Related]

  • 19. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rümke P, Melief CJ.
    Cancer Res; 1989 Jul 15; 49(14):3783-8. PubMed ID: 2472198
    [Abstract] [Full Text] [Related]

  • 20. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.
    Myers DE, Uckun FM.
    Leuk Lymphoma; 1995 Jun 15; 18(1-2):119-22. PubMed ID: 8580813
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.